Pharming Group N.V./€PHARM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.
- Ticker
- €PHARM
- Sector
- Health
- Primary listing
- AEX
- Employees
- 407
- Headquarters
- Leiden, Netherlands
- Website
- www.pharming.com
PHARM Metrics
BasicAdvanced
€771M
42.18
€0.03
0.07
-
Price and volume
Market cap
€771M
Beta
0.07
52-week high
€1.81
52-week low
€0.82
Average daily volume
9.1M
Financial strength
Current ratio
3.225
Quick ratio
2.645
Long term debt to equity
0.362
Total debt to equity
0.393
Interest coverage (TTM)
8.50%
Profitability
EBITDA (TTM)
51.094
Gross margin (TTM)
87.67%
Net profit margin (TTM)
6.25%
Operating margin (TTM)
12.78%
Effective tax rate (TTM)
29.56%
Revenue per employee (TTM)
€851,380
Management effectiveness
Return on assets (TTM)
6.37%
Return on equity (TTM)
8.70%
Valuation
Price to earnings (TTM)
42.182
Price to revenue (TTM)
2.339
Price to book
2.56
Price to tangible book (TTM)
4.5
Price to free cash flow (TTM)
26.225
Free cash flow yield (TTM)
3.81%
Free cash flow per share (TTM)
0.041
Growth
Revenue change (TTM)
6.76%
Earnings per share change (TTM)
13,053.67%
3-year revenue growth (CAGR)
20.92%
10-year revenue growth (CAGR)
40.93%
3-year earnings per share growth (CAGR)
-5.25%
10-year earnings per share growth (CAGR)
-3.41%
What the Analysts think about PHARM
Analyst ratings (Buy, Hold, Sell) for Pharming Group N.V. stock.
Analyst projections of the future price of Pharming Group N.V. stock.
Bulls say / Bears say
Preliminary third-quarter revenue rose 21% year on year to US$117.6 million, with RUCONEST up 14% and Joenja up 58%; operating expenses were roughly flat. This points to a return to growth after a weaker first half, with Joenja contributing more to sales. (Pharming)
Leniolisib could extend beyond APDS: Pharming reported positive Phase II data in genetically defined primary immunodeficiencies and expects CVID trial results in November. The company estimates CVID with immune dysregulation affects a substantially larger population than APDS. (Pharming)
RUCONEST remains exposed to competition and sales volatility: first-half revenue fell 12% year on year, while the third-quarter rebound included an early inventory build at one US specialty-pharmacy customer. That makes it harder to tell how much of the latest recovery reflects lasting demand. (Pharming, Pharming)
Cash generation weakened in the first half: Pharming recorded a US$3.6 million operating loss and used US$7.7 million of cash in operations, while cash and marketable securities fell by US$21.6 million to US$159.5 million. This shows commercial growth has not yet translated into dependable cash generation. (SEC)
The napazimone pipeline catalyst has slipped: Pharming now expects to complete enrolment in its pivotal FALCON study in the first half of 2027, later than its prior year-end 2026 target. Top-line results are expected about a year after enrolment finishes, extending the wait for evidence on the programme. (Pharming)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
PHARM Financial Performance
Revenues and expenses
PHARM Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PHARM
Fund name | Fund size | €PHARM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.08% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.08% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.